Introduction {#sec0001}
============

Neuber was first to describe the transfer of fat as a means of treating retractile scarring in 1893.[@bib0001] Fat grafting, however, has only gained widespread popularity amongst plastic surgeons over the past several decades. Its use as a treatment for both cosmetic and reconstructive contour defects has evolved due to the development of modern liposuction in the 1980's by Illouz[@bib0002]^,^[@bib0003] and the continued refinement of harvesting, preparation and grafting techniques such as those pioneered by Coleman.[@bib0004]

Fat serves as ideal soft tissue filler in that it is autologous, biocompatible, easily accessible in most patients, relatively permanent and can integrate into the surrounding tissue at the injection site.[@bib0004], [@bib0005]^--^[@bib0006] The safety and effectiveness of fat grafting has been extensively studied for various indications, particularly in breast surgery for both reconstructive and cosmetic purposes.[@bib0007]^--^[@bib0009] Its use in the facial region has also increased, although less is published regarding its safety and effectiveness for facial reconstruction or aesthetic improvement.[@bib0008]^,^[@bib0010], [@bib0011]

To that end, the authors have performed a systematic review of the literature, with the objective of providing more data with which to evaluate the effectiveness and associated complications of autologous fat grafting for the treatment of contour deformities in facial region.

Patients and methods {#sec0002}
====================

A search of the National Library of Medicine (PubMed), MEDLINE, and Cochrane databases was conducted using different versions of the following keywords: \[("fat graft" or "autologous graft" (MESH), or "adipose") and ("graft survival" (MESH), or "complications", or "treatment outcomes" (MESH))\]. The search was confined to both English and French language articles and limited to humans. Articles from all years up until December 2015 were considered, with no restriction placed on patient age.

The resultant 789 abstracts were independently assessed by two separate reviewers according to strict inclusion and exclusion criteria. Studies were included if data regarding facial fat grafting complication rates and/or efficacy was provided. Patients receiving fat grafting as an adjunct to another therapy or dermal fat grafting were excluded in order to decrease confounding factors and to more accurately assess graft retention and complications attributed solely to fat grafting. Case reports were also excluded to limit publication bias. No limitation was placed on minimum follow up time. Forty-three full articles were retained based on our inclusion criteria of facial contour defects and the use of fat grafting as the sole treatment modality.

The selected articles were analyzed regarding patient demographics, indication for treatment, harvest site, processing technique, graft enrichment, injection site, volume injected, percentage of graft retained, follow up time and complications resulting from the procedure.

Given the large variability in the method by which injection sites were documented, cases were categorized according to anatomic facial regions treated: upper, middle, and lower. The upper third was defined as the region extending from the hairline to glabella, the middle third from glabella to subnasale and the lower third from subnasale to menton.

Complications included in the analysis were erythema, prolonged edema (lasting greater than 3 weeks), telangiectasia, asymmetry, skin irregularities, graft hypertrophy, erythema, infection and fat necrosis.

The reported volume of adipose tissue retained at follow up in various studies was measured using 2-dimensional photography, 3-dimensional imaging or commuted tomography (CT) scans.

This systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)[@bib0012] ([Figure 1](#fig0001){ref-type="fig"}, [Table 1](#tbl0001){ref-type="table"}).[@bib0006], [@bib0013]^--^[@bib0054]Figure 1Flowchart of search criteria and strategy used for performance of the literature review in accordance with PRISMA guidelines.Figure 1Table 1Overview of included studies characteristics and level of evidence.Table 1StudyYearStudy designNumber of patientsEvidence levelAzzam et al.[@bib0014]2013Cohort203Baptista et al.[@bib0015]2013Case series204Castor et al.[@bib0016]1999Cohort64Caye et al.[@bib0017]2003Case series294Cervelli et al.[@bib0018]2014Case series454Chang et al.[@bib0019]2013Cohort203Coleman[@bib0006]2006Case series34Dollfus et al.[@bib0020]2009Case series64Duskova and Kristen[@bib0021]2004Case series54Erol and Agaoglu[@bib0022]2013Case series24394Ersek et al.[@bib0023]1998Case series44Fontedevila et al.[@bib0024]2014Randomized controlled trial492Fontedevila et al.[@bib0025]2008Case series264Gentile et al.[@bib0026]2014Cohort203Gerth et al.[@bib0027]2014Cohort263Guaraldi et al.[@bib0028]2005Cohort243Guibert et al.[@bib0029]2013Case series114Guijarro et al.[@bib0030]2011Case series114Guyuron and Majzoub[@bib0031]2007Case series164Jianhui et al.[@bib0032]2014Cohort363Kanchwala et al.[@bib0033]2005Cohort9763Khater et al.[@bib0034]2009Cohort513Kim et al.[@bib0035]2010Case series64Kuran and Tumerdem[@bib0036]2005Case series714Laurent et al.[@bib0037]2006Case series94Li et al.[@bib0038]2013Case control384Lim et al.[@bib0039]2012Case series274Mojallal et al.[@bib0040]2015Case series1004Monreal[@bib0041]2011Case series334Ozkaya et al.[@bib0042]2013Case series214Rauso et al.[@bib0043]2011Cohort234Rusciani et al.[@bib0044]2012Case series2154Sasaki[@bib0045]2011Case series234Schendel[@bib0046]2015Cohort103Stereodimas et al.[@bib0047]2011Cohort203Tsai and Liao[@bib0048]2010Case series2094Wang et al.[@bib0049]2015Case series1054Xie et al.[@bib0050]2007Case series314Xie et al.[@bib0053]2010Case series834Yin et al.[@bib0051]2013Case series124Yoshimura et al.[@bib0013]2008Cohort64Zeltzer et al.[@bib0052]2012Case series2504Zhu et al. [@bib0054]2016Case series224

Results {#sec0003}
=======

Our search returned 789 matches, 43 of which met our inclusion criteria, representing a total of 4577 individual patients who underwent autologous fat transfer.[@bib0006], [@bib0013]^--^[@bib0054]

Patient demographics/characteristics {#sec0004}
------------------------------------

Of the 4577 included patients who underwent autologous fat transfer, 55% (*n *= 2516) were female and 12.1% were male (n=553), with the remaining 32.9% (*n *= 1508) not specified. The mean age at the time of the procedure was 36.2 years (range: 7.4--80 years) ([Table 2](#tbl0002){ref-type="table"}).Table 2Study characteristics.Table 2CharacteristicsOverall *n* =Patients treated4577Gender (%) Female2516 (55) Male553 (12.1) Unspecified1508 (32.9)Age (years) Mean36.2 Range7.4--80Indication (%) Cosmetic1538 (75.39) Lipodystrophy170 (8.33) Post-op defects96 (4.71) Hemifacial atrophy94 (4.61) Congenital43 (2.11) Trauma33 (1.61) Burns30 (1.47) Scarring23 (1.13) Other14 (0.69)Volume injection (cc) Mean16.9 Range1--133Injection sites (volume injected in cc) Upper393 (11.8) Middle1234 (16.2) Lower248 (7.8)Follow-up (months) Mean13.95 Median12

The indications for treatment were clearly documented in 2040 cases. In decreasing order of prevalence, they were: cosmetic 75.39% (*n *= 1538), lipodystrophy 8.33% (*n *= 170), post-operative defects 4.71% (*n *= 96), hemifacial atrophy 4.61% (*n *= 94), other congenital malformations 2.11% (*n *= 43), trauma 1.61% (*n *= 33), burns 1.47% (*n *= 30), scarring 1.13% (*n *= 23) and other 0.69% (*n *= 14).

Injection characteristics {#sec0005}
-------------------------

A total of 1875 procedures with clearly documented anatomic recipient sites were identified. The fat injection sites were divided according to anatomic facial regions treated, corresponding to upper (*n *= 393), middle (*n *= 1234) and lower third (*n* = 248). The mean volume injected across all anatomical regions was 16.9cc (range 1--133cc). The mean volume by facial region was upper 11.8cc, middle 16.2cc and lower third 7.8cc.

Follow-up {#sec0006}
---------

The mean follow up time was 13.95 months and median time was 12 months. The reported follow up periods ranged from 3 months to 50 months.

Graft enrichment {#sec0007}
----------------

Graft enrichment was documented in 2.38% of patients (*n *= 109) and consisted of either adipose tissue supplemented with stromal vascular fraction (SVF) (*n *= 79) or platelet rich plasma (PRP) (*n *= 30).

Processing technique {#sec0008}
--------------------

A total of seven graft-processing techniques were documented in 38 studies. The Coleman technique was the most commonly used method across all studies. Two studies utilized more than one processing technique. Washing was performed using saline solution in all patients ([Table 3](#tbl0003){ref-type="table"}).Table 3Detailed breakdown of fat harvesting techniques.Table 3TechniqueNumber of patientsNumber of studiesColeman67621Washing4038Non-centrifuged414Low-pressure1524Coleman + antibiotics24391Washed + centrifuged101Closed-membrane filtration191Total374040

Harvest site {#sec0009}
------------

No preferred donor site was identified throughout the included studies. Adipose tissue was harvested from the abdomen, flanks, thighs, dorsal cervical hump, and buttocks, and was determined primarily based on surgeon and patient preference.

Complications {#sec0010}
-------------

An overall complication rate of 2.27% (*n* = 104) was noted amongst all studies. The most commonly documented complications were asymmetry, skin irregularities, hypertrophy, prolonged edema (lasting greater than 3 weeks), fat necrosis, infection, telangiectasia, erythema and activation of acne ([Table 4](#tbl0004){ref-type="table"}, [Table 5](#tbl0005){ref-type="table"}, [Table 6](#tbl0006){ref-type="table"}).Table 4Reported complications of fat grafting.Table 4ComplicationNumber of patientsPercentage of all complications (%)Asymmetry7471.15Skin irregularities1413.46Hypertrophy43.85Prolonged edema43.85Fat necrosis32.88Infection21.92Telangiectasias10.96Erythema10.96Activation of acne10.96Table 5Complications of fat grafting stratified according to site of injection.Table 5Facial regionComplicationNumber of complications (%)Total number of injectionsUpperInfection1 (0.40)248MiddleAsymmetry9 (0.73)1234Erythema1 (0.08)Hypertrophy4 (0.32)Skin irregularities2 (0.16)LowerEdema1 (0.25)393Table 6Complications of fat grafting stratified according to procedural indication.Table 6IndicationComplicationNumber of complications (%)Total number of injectionsCosmeticAsymmetry60 (3.90)1538Fat necrosis2 (0.13)Infection1 (0.06)LipodystrophyAsymmetry11 (6.47)170Hypertrophy4 (2.35)Skin irregularities3 (1.76)Post-operative defectInfection1 (1.04)96Telangiectasia1 (1.04)ScarActivation of acne1 (4.35)23Prolonged edema1 (4.35)Erythema1 (4.35)

Volume retention at follow-up {#sec0011}
-----------------------------

The mean weighted volume of fat graft retention was stratified according to procedural indication, anatomical region of injection and processing technique. In addition, the mean retention was also calculated for grafts enriched with SVF and PRP.

Twelve studies documented the method used for quantifying the percentage of adipose tissue retained at follow-up. Two studies used two-dimensional photographs, six studies used a form of three-dimensional imaging, and four studies used computed tomography scanning ([Table 7](#tbl0007){ref-type="table"}).Table 7Detailed breakdown of the mean volume fat graft retention.Table 7Characteristics (number of cases)Retention percentage (%)Indication Cosmetic (56)45.76 Reconstructive (72)38.26Injection site Upper (61)35.80 Middle (31)41.50 Lower (12)51.88Processing technique Coleman (88)41.00 Low-pressure (22)44.53 Closed-membrane filtration (19)41.20 Non-enriched (129)41.63Enriched SVF (56)65.68 PRP (10)69.00 Cosmetic SVF (36)65.69 Reconstructive SVF (20)65.65 Reconstructive PRP (10)69.00 Coleman SVF (46)65.17 Coleman PRP (10)69.00 Washed + centrifuged SVF (10)68.00[^1]

Discussion {#sec0012}
==========

Autologous fat grafting has many beneficial qualities that make it advantageous for correcting contour deformities or augmenting soft-tissue for reconstructive or cosmetic indications. Fat grafts are autologous, biocompatible, permanent and viable when integrated into the injection site. They are easily accessible in most patients, and represent a relatively simple and low-cost surgical procedure. Many studies have demonstrated that in addition to the volume provided, adipose tissue contains both adipose-derived stem cells (ASC) as well as multipotent stems cells, which can differentiate into various tissue types.[@bib0055], [@bib0056], [@bib0057], [@bib0058], [@bib0059]^--^[@bib0060] Not only can ASCs differentiate into adipocytes and contribute to the regeneration of adipose tissue, but they have also been shown to promote angiogenesis through the release of growth factors in response to hypoxic microenvironements.[@bib0055]^--^[@bib0060] The fact that these growths factors influence the surrounding host tissue has been advantageously used to improve healing in conditions such as in radiation dermatitis or chronic ulcerations.[@bib0060], [@bib0061], [@bib0062]^--^[@bib0063]

The results of the present study serve to expand the existing body of literature and provide more complete evidence, pooled from the existing data, describing the effectiveness and safety of autologous fat grafting for the treatment of facial contour defects. This study illustrates the versatility of fat grafting, while also highlighting important details such as complication rates and rates of graft retention relative to anatomic regions of the face and processing techniques.

The complication rate (2.27%) identified in this review was minimal, with the majority of complications (84.61%) being attributed to either asymmetry or skin irregularities (excessive or inadequate grafting or graft survival). Fat necrosis (*n* = 3) and infection (*n *= 2) represented 2.88% and 1.92% of all complications, respectively. These results differ from those seen in fat grafting used for both breast and gluteal augmentation. In the systematic review by Voglimacci et al.,[@bib0007] the authors reported a complication rate of 12.6% in cosmetic breast fat grafting. Of the 256 documented complications, there were 60 cases of fat necrosis (23.44% of all complications), and 18 cases of infection (7.03% of all complications). Conde-Green et al.[@bib0064] reported an overall complication rate of 7% in gluteal fat augmentation, of which there were 24 cases of infection (8.33% of all complications), and 23 cases of fat necrosis (7.99% of all complications).

Although not documented in this review, there have been anecdotal and published reports of significant patient morbidity and mortality as a result of fat emboli.[@bib0010]^,^[@bib0065], [@bib0066], [@bib0067]^--^[@bib0068] Cases of emboli following autologous fat grafting to the glabella and nose have been attributed to retrograde arterial injection, facilitated by the abundant vascular supply in these regions, notably the frontal and dorsal nasal arteries that are supplied by the ophthalmic artery.[@bib0065], [@bib0066], [@bib0067], [@bib0068], [@bib0069], [@bib0070]^--^[@bib0071] Conversely, emboli in the gluteal region are often due to inadvertent injection into large caliber veins. Certain studies have therefore suggested using blunt cannulas to minimize this risk during injection in addition to aspiration prior to injection.[@bib0010], [@bib0072], [@bib0073] Unfortunately, there was insufficient data in the analyzed papers to validate this claim. In the present review, there were no reports of mortality or significant embolic complications associated with facial fat grafting procedures.

The mean volume of fat retained of non-enriched grafts was found to be 41.63% (*n *= 129). The mean volume retained of fat enriched with SVF was 65.68% (*n *= 56), while grafts enriched with PRP was 69% (*n *= 10). Despite the limited sample size, discrepancy in the methods of fat volume retention assessment and follow-up intervals, these results parallel the survival of fat grafts to anatomical regions other than the facial region.[@bib0007], [@bib0008], [@bib0010], [@bib0074] In a recent systematic review by Zhou et al.[@bib0010] evaluating graft survival based on technique, the authors reported a statistically significantly higher facial fat graft survival rate of 71% in the cell-assisted lipotransfer group as compared to 52% in the control group (standard fat grafting). It has been hypothesized that cell assisted-lipotransfer would increase fat survival by enhancing angiogenesis and adipogensis.[@bib0075], [@bib0076] However, current lipotransfer techniques are not reliably capable of reversing the central ischemia of larger volume grafts.[@bib0063]

The mean weighted volume of retained fat was stratified according to procedural indication, injection site and processing technique. The difference of retained volume in these subgroups was minimal. When comparing Coleman, low-pressure and closed-membrane filtration, the retained volumes were 41.00%, 44.53%, and 41.20%, respectively. These results are in keeping with a systematic review conducted by Gupta et al.,[@bib0011] in which the authors were unable to identify one processing technique that was superior to the others. It was postulated, however, that a combination of gentle washing and centrifugation should be employed to preserve adipocyte viability while removing the bulk of the contaminants. The studies included in this review that utilized washing as their graft processing technique did not publish graft survival rates.[@bib0024], [@bib0036], [@bib0038], [@bib0043], [@bib0046], [@bib0049], [@bib0051], [@bib0053]

Graft retention for facial cosmetic and reconstructive indications was 45.76% and 38.26%, respectively. These results fall within the wide range of values reported for fat grafting to the breast (range 34%--82%). [@bib0007]^--^[@bib0009], [@bib0077] Fat retention appears to be comparable for both cosmetic and reconstructive groups of patients, however, it was difficult to accurately assess given the vast spectrum of reconstructive indications, and the variability by which the retained volume was calculated. To that end, there is currently not enough data in the published literature to draw conclusions as to the superior indication (reconstruction vs. aesthetic) or processing technique for fat grafting.[@bib0010], [@bib0011], [@bib0064] Furthermore, a surrogate marker used to determine whether the outcome of the procedure was successful was patient and surgeon satisfaction. Objective measurement of satisfactory outcomes using questionnaires was only reported in a subset of studies, while the remainder relied on surgeon interpretation.[@bib0014]^,^[@bib0018]^,^[@bib0022]^,^[@bib0029]^,^[@bib0030]^,^[@bib0034]^,^[@bib0035]^,^[@bib0040]^,^[@bib0049]^,^[@bib0050]

Despite the comprehensive nature of this study, there are several inherent limitations of this review. The majority of the articles included were case series, with low levels of evidence, which introduces a risk of publication bias. The way in which information was documented and presented in the various included studies was heterogeneous. While some studies provided detailed demographics for each individual patient, others simply provided overall averages of their patient population, which prevented the use of a meta-analysis technique and statistical analysis to compare groups with the compiled data (i.e. complication rates by facial region or processing technique). Given that the majority of complications were minor and likely more subjective depending on the surgeon, it is also possible that the true complication rates were underestimated. Heterogeneity in fat injection technique (i.e. syringe size, cannula size, rate of injection, volume of injection etc.) could significantly impact volume retention, a confounding factor that could not be accounted for in this review. Lastly, the methods used to assess graft survival varied in terms of length of follow-up (range 3--50.76 months) and method of volumetric analysis. Shorter follow-up may favor greater retained (reported) volume, as graft retention has been shown to stabilize between 5 and 12 months post-operatively.[@bib0072], [@bib0074] Additionally, two of the twelve studies (16.7%) only utilized two-dimensional photography to assess graft retention, which allows for greater subjectivity when assessing the results.

The present study is the first systematic review of fat grafting in the facial region. Although limited in its ability to statistically analyze the published data, it does pool and summarize existing literature to provide a more comprehensive review of our current state of knowledge for this commonly performed procedure. Important information such as average retained grafting volumes and complication rates are presented to provide clinicians with more accurate information with which to guide their decision-making and patient education for facial fat grafting procedures.
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[^1]: SVF, stromal vascular fraction; PRP, platelet-rich plasma.
